High Hopes For Heidelberg Pharma With Huadong Onboard
Pact With Chinese Group Close To Completion
CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.
